Clinical TrialsThe FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Synexis to resume the study.
Financial StabilityScynexis has $53M in cash as of the end of 1Q25 which should provide runway into mid-2026, so the MARIO trial can continue.
Product ApprovalBrexafemme, the first-in-class triterpenoid antifungal, has broad-spectrum fungicidal activity and is approved for vulvovaginal candidiasis.